Difficulties encountered when treating coeliac disease : from molecule to miracle cure? by Pullicino, Edgar
Malta Medical Journal    Volume 19   Issue 02   June 2007 
Edgar Pullicino
Review Article
Difficulties encountered 
when treating coeliac disease:  
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Abstract
Dietary treatment of coeliac disease should be based on a 
sound theoretical knowledge of the different immunogenicities 
of various cereal grains, an appreciation of the limitations 
of the current Codex Alimentarius recommendations and an 
understanding of the factors that limit dietary compliance in 
many patients. The expertise of dieticians, nutritional chemists, 
gastroenterologists and clinical pharmacists should be made 
readily available to coeliac patients, to coeliac societies and to 
coeliac self-help groups. Various enzymatic and pharmacological 
modalities that may be used to treat coeliac disease in the future 
are highlighted as potential ways to improve quality of life in 
these patients in whom the coeliac diet often promotes poor 
compliance or may lead to significant social alienation.
Know your grains; know your glutens
The seeds of wild grasses eaten by nomadic primitive 
hunter-gatherers were sown and harvested by primitive 
urban settlers to produce today’s cereal grains.  Milling and 
grinding allowed brewing and baking by releasing starches 
in the inner “endosperm” from the husk and outer coatings. 
Wheat endosperm, which is the food store for the embryo in 
the wheat grain contains oils, carbohydrates and proteins. 
Cereal proteins include albumin, globulin, alcohol-insoluble 
glutens and the alcohol-soluble prolamins which may trigger 
coeliac disease.  Glutens are complex polymers with molecular 
weights of several million that give bread dough the viscoelastic 
properties that favour baking.  The prolamines implicated in 
coeliac disease (CD) contain a high content of glutamine: namely 
gliadin in wheat, hordeins in barley and secalins in rye.  Oat 
prolamines called avenins are more distantly related to wheat. 
The mechanisms by which these prolamines cause immune 
damage in coeliac patients have been outlined in a previous 
issue of this Journal.
Treating the patient:  where do we start?
A gluten-free diet remains the cornerstone of treatment but 
presents several theoretical and practical difficulties.  Wheat, 
rye, and barley must be excluded as their prolamines (30-50%) 
contain many immunogenic peptides. Corn and rice are not 
immunogenic. Oats are traditionally allowed as their prolamins 
(5-15% by weight) contain less glutamine and are of low 
immunogenicity except in occasional individuals.  Intolerance to 
oats is often due to contamination with other prolamins during 
processing in mills used to grind wheat.
How low should we go?
The minimum amount of gluten allowed in the diet continues 
to be debated.  In 1980 the Codex Alimentarius commission 
(FAOUN/WHO)1   stated that food labeled “gluten-free” 
should contain less that 0.03% of total protein derived from 
wheat, barely, rye or oats.  A stringent limit of 20mg gluten 
per kg of food rendered gluten-free during processing is 
being considered. CD patients ingesting less that 1g gluten 
per day in one study and less that 2.5-5.0g gluten per day in 
another study showed increased numbers of Intra epithelial 
lymphocytes (IELs) in their duodenal biopsies but their villous 
architecture was normal.  Collin et al2  showed that since flour 
intake rarely exceeds 300g per day in coeliac patients, a limit 
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of 100mg/kg food (30mg gluten intake) is compatible with 
normal duodenal histology, is easily achieved by industry, 
and being less stringent should encourage longer and better 
compliance.  The Codex recommendations are not immune 
from bias arising from a producer lobby and should be based 
on more rigorous studies of the clinical effects of various long-
term gluten intakes.  Enforcement of a Codex standard by a food 
or medicines regulatory authority is limited by the “sandwich 
ELISA” method used by Food Standard Laboratories to verity 
the manufacturer’s gluten-free labelling.  This assay allows for 
different gliadins present in gluten and for their susceptibility to 
heat during manufacture but may not identify many of the toxic 
gliadin epitopes present inside gliadin fragments.3
Administrating the coeliac diet:  
how do we go about it?
Newly diagnosed coeliac patients require a nutritional 
assessment before referral to a state-registered dietician for 
dietary advice and long-term supervision.  Children may show 
poor linear growth while adults may show suboptimal body mass 
index or irreversible short stature at presentation. Folate and 
iron deficiency may require specific replacement. The prescribed 
“gluten-free diet” (GFD) may be low in folate derived from 
cereals and in energy. Up to 50% of newly diagnosed patients 
will be osteopenic or osteoporotic on DEXA bone density 
measurement. Calcium and vitamin D malabsorption may be 
associated with raised serum bone-derived alkaline phosphatase 
isoenzyme and elevated serum parathyroid hormone levels. The 
GFD should include abundant milk products but calcium and 
vitamin D supplementation may be needed if the patients are 
milk-intolerant.  
The principles of substituting bread, pasta and wheat cereals 
with alternatives such as rice, corn, millet and buckwheat should 
be explained.  The patient should be encouraged to react to 
and understand food labels and to consult food lists published 
by National Coeliac Societies4, local coeliac self-help groups 
or web-based support pages5 when purchasing refined foods 
which often incorporate wheat based emulsifiers or colouring 
additives. Further education can be achieved by the dieticians 
through local support groups.
Defective compliance to a GFD still causes major limitations 
during long-term care. Compliance is highest in patients 
diagnosed at a young age and lower in adults (e.g. 17-45%) 
than in teenagers (typically 56-83%).  Resolution of symptoms, 
particularly abdominal pain occurs in most patients, on GFD 
even when serological or biopsy response is incomplete and 
constitutes the main incentive for continued strict compliance. 
Poor symptom resolution is commonly due to inadvertent 
gluten consumption (e.g. in medications or fibre additives), 
persistent lactose intolerance, associated microscopic colitis, 
refractory sprue, ulcerative jejunitis or emergent T-cell intestinal 
lymphoma.  Compliance is often reduced when gluten-free foods 
are expensive and only partly subsidised by health services, 
have low palatability, unattractive colour or consistency, or are 
available in a limited range.  The availability of gluten-free foods 
on prescription in Malta has had immediate tangible effects on 
patient compliance.  Communal eating in restaurants or when 
travelling, reduces availability and exerts a societal pressure to 
relapse. Unsupervised children often have relapses at school. 
Absence of symptoms immediately after cheating may worsen 
poor resolve or sub-conscious procrastination to adhere strictly 
to a GFD.  
High serum antigliadin IgA antibodies return to normal 
levels in about 75% or patients compliant to a GFD and rise again 
rapidly after a gluten challenge.  Serum tissue transglutaminase 
(tTG) levels often reflect the level of compliance to GFD in 
patients whose sera were initially positive for antiendomysial 
antibody but do not reflect mucosal recovery.  Repeat duodenal 
biopsy may be necessary in compliant patients with persistently 
raised serum tTG or persistent symptoms.
Even with excellent compliance, a well-supervised diet may 
cause problems.  Berti et. al6 showed that the digestibility of 
the starch component of various processed gluten-free foods 
using in-vitro multi-enzyme digestion was higher than that in 
gluten-rich foods.  Gluten-free foods were shown to produce a 
higher glycaemic response resulting in higher circulating blood 
glucose concentrations.  These findings are of concern given that 
diabetes mellitus occurs in about 5% of coeliac patients.  Some 
patients fail to gain weight or height despite adequate dietary 
compliance due to undiagnosed diabetes, thyroid disease or 
adrenal insufficiency which are known associations of CD.  The 
chromosomal associations of CD, namely Down’s syndrome 
and Turner’s syndrome will also cause persistent short stature. 
Some patients will remain underweight because they become 
more health-conscious at diagnosis and limit their dietary 
energy intake while others who fail to compensate for reversed 
malabsorption develop new-onset obesity.
CD patients require regular follow up by a multidisciplinary 
team supervised by an adult or paediatric gastroenterologist 
employing a nutritionist, dietician, clinical pharmacist 
and a specialist nurse in liaison with a rheumatologist 
and endocrinologist who should all be accessible to CD 
patient-support groups.  A clinical pharmacist is often 
consulted regarding the gluten content of various medicinal 
preparations.  
Even with best of care many patients on GFD report a low 
self-rated level of happiness.7  The main impact of CD on quality 
of life in diet-compliant patients does not result from coeliac-
related symptoms but from social alienation secondary to a 
restricted diet when eating out or travelling.
Sliced bread or spliced peptides:  
a taste of future treatment
A close look at the pathogenetic cascade of events leading 
to mucosal damage, as described in the previous issue of this 
Journal identifies several steps which may be amenable to 
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novel therapeutic approaches thus allowing more gluten to be 
incorporated in future coeliac diets.
1. The discovery that certain gliadin peptides (e.g. 
aminoacids 62-75 and 57-68 in A gliadin) are 
immunodominant8, i.e. they consistently elicit an 
immune response from intestinal T-cells, has prompted 
food research chemists to modify or delete these amino 
acid sequences in dietary A gliadin to produce a non-
toxic genetically modified flour.  Alternatively, different 
varieties of natural wheat can be screened for gliadins 
with less toxic properties.
2. An alternative approach could incorporate into wheat 
products, enzymes capable of hydrolysing toxic peptides 
in the intestinal lumen at multiple peptide bonds so as to 
disrupt their antigenic sequences.  Such enzymes would 
have to be acid and pepsin-stable, and ideally heat labile 
to allow baking.  A number of prolyl endopeptidases 
(PREP) from different sources active at intestinal pH (pH 
6-7) are being evaluated,9 but there is concern that the 
enzyme may not penetrate chyme fast enough to clear 
all immunogenic peptides.  The oral enzymatic approach 
was prompted by the observation that many coeliac 
patients exhibit upregulation of the PREP gene suggesting 
that a defect in the function of PREP allows survival of 
large uncleaved immunogenic peptides in the intestinal 
lumen.10
3. Since intestinal bacteria may increase exposure of antigen 
presenting cells to immunogenic peptides by widening the 
tight junction between enterocytes11 and because gluten-
ingesting bacteria may also be sampled by dendritic 
cells, probiotics or antibiotics are alternative candidate 
pharmacological treatments for CD.
4. Once gliadin epitopes have gained access to the 
submucosa, the next step in the pathogenesis is 
the tTG-mediated cross-linking of glidadin and the 
deamidation of glycine residues on gliadin epitopes. 
Cross-linking increases the availability of toxic epitopes 
in the submucosa and deamidation facilitates binding 
of epitopes to DQ2 or DQ8 glycoproteins on antigen 
presenting cells.  Orally administered peptides that 
inhibit tTG would reduce disease activity by inactivating 
this key enzyme and auto-antigen.  However since the 
tTG family of enzymes are responsible for regulating 
apoptosis and stabilizing connective tissue in a number of 
organs, these oral peptides are unlikely to be safe.12 
5. Further down the immunological cascade there is interest 
in designing inhibitors that would block the binding 
of epitopes to DQ2 and DQ8 molecules on antigen 
presenting cells.  This still represents a targeted approach 
as it would not disturb the binding of other important 
antigens.
6. Less specific would be the administration of cytokines 
such as IL-10 which make the dendritic cell tolerogenic, 
ultimately leading to active suppression and anergy of T 
cells.13  This would avoid stimulation of T-cell receptors 
which usually results in a Th
1
 cytokine-mediated 
apoptosis and a Th
2
 response that promotes B-cells to 
produce antibodies to gluten and tTG.14
7. Treatment with prednisolone is reserved for patients 
who remain severely symptomatic and whose  intestinal 
biopsies fail to resolve on a strict GFD.  Azathioprine 
has been used as a steroid sparing agent with variable 
success.15  Intravenous cyclosporine may be indicated in 
ill patients who do not respond to steroid treatment.16  
Coeliac disease which is refractory to diet is less likely 
to respond to steroids and azathioprine when IELs are 
phenotypically immature and lack characteristic T cell 
markers.  Many of these steroid–resistant cases harbour 
or eventually develop small intestinal T cell lymphomas.15  
Conclusion
Life long adherence to a strict gluten-free diet, backed by 
strategies that maximize dietary compliance remain the most 
effective modality to manage coeliac disease.  Understandably 
dietary guidelines cannot be refined until the whole spectrum 
of immunodominant peptides has been unravelled. Maximum 
safe limits in daily consumption of those dietary peptides that 
are compatible with normalization of intestinal biopsies still 
need to be determined.  Future dietary treatments may utilize 
genetically modified cereal proteins or peptides that have been 
modified by prolylpeptidases during food preparation or during 
luminal digestion.  
The discovery of several key protagonists in the long sequence 
of antigen processing and presentation of modified antigen to the 
immune system introduces many possibilities for attenuating 
immune damage at an early stage in the immune cascade, ideally 
before amplification by cytokines has taken place.  However 
more basic research is required before pharmacologic therapy 
can be proposed as an alternative or as an adjunct to dietary 
management.
Therefore more scientific research is likely to be required 
before focusing on clinical trials of genetically modified cereal 
foods in celiac disease.  
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